Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RT Developing best-in-class radiopharmaceuticals for cancer treatment | $70M | Series CSeries C+ | Biotech | United States | Investors | |
| AT Adjuvia TherapeuticsCompany profile Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. | $8M | Seed | Biotech | United States | Investors | |
| TB Developing nerve-targeted imaging technologies for surgery. | Undisclosed | Series A | Biotech | United States | Investors | |
| CB CORE BiomedicineCompany profile Developing the next generation of precision medicines by going beyond genomics. Developing the next generation of precision medicines by going beyond genomics. | $21M | Series A | Biotech | United States | Investors | |
| TP Torrey Pines MedicineCompany profile Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases | Undisclosed | Pre-SeedPre-seed | Biotech | China | Investors | |
| VD Vivid DxCompany profile Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions | $15M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| M MiraeCompany profile AI-driven continuous care platform for autoimmune disease and other complex chronic conditions AI-driven continuous care platform for autoimmune disease and other complex chronic conditions | $5.4M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| MT Moa TechnologyCompany profile An agricultural biotechnology company focused on discovering novel mode of action herbicides An agricultural biotechnology company focused on discovering novel mode of action herbicides | £22.2M | Series CSeries C+ | Biotech, Agritech | United Kingdom | Investors | |
| TA Tikva AllocellCompany profile Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors | $8M | Series A | Biotech | Singapore | Investors | |
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.